Rheumatology International

, Volume 32, Issue 2, pp 427–430 | Cite as

Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromialgia patients

  • Flávia Regina Barbosa
  • Josie Budag Matsuda
  • Mendelson Mazucato
  • Suzelei de Castro França
  • Sônia Marli Zingaretti
  • Lucienir Maria da Silva
  • Nilce Maria Martinez-Rossi
  • Milton Faria Júnior
  • Mozart Marins
  • Ana Lúcia FachinEmail author
Original Article


Fibromyalgia syndrome (FS) is a rheumatic syndrome affecting to 2–3% of individuals of productive age, mainly women. Neuroendocrine and genetic factors may play a significant role in development of the disease which is characterized by diffuse chronic pain and presence of tender points. Several studies have suggested an association between FS, especially pain sensitivity, and polymorphism of the catechol-O-methyltransferase (COMT) gene. The aim of the present study was to characterize the SNPs rs4680 and rs4818 of the COMT gene and assess its influence in pain sensitivity of patients with fibromyalgia screened by the Fibromyalgia Impact Questionnaire (FIQ). DNA was extracted from peripheral blood of 112 patients with fibromyalgia and 110 healthy individuals and was used as template in PCR for amplification of a 185-bp fragment of the COMT gene. The amplified fragment was sequenced for analyses of the SNPs rs4680 and rs4818. The frequency of mutant genotype AA of SNP rs6860 was 77.67% in patients with FS and 28.18% for the control group. For the SNP rs4818, the frequency of mutant genotype CC was 73.21 and 39.09% for patients with FS and controls, respectively. Moreover, the FIQ score was higher in patients with the homozygous mutant genotype for SNPs rs4680 (87.92 points) and rs4818 (86.14 points). These results suggest that SNPs rs4680 and rs4818 of the COMT gene may be associated with fibromyalgia and pain sensitivity in FS Brazilian patients.


Fibromyalgia Genetic polymorphisms Pain sensitive FIQ 



We thank the patients and controls who donated blood for this study.


  1. 1.
    Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH (2001) Cytokines play an aetiopathogenic role in fibromialgia: a hypothesis and pilot study. Rheumatology 40:743–749PubMedCrossRefGoogle Scholar
  2. 2.
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 33:160–172PubMedCrossRefGoogle Scholar
  3. 3.
    Carmona L, Ballina J, Gabriel R, Laffon A (2001) EPISER study group: the burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60:1040–1045PubMedCrossRefGoogle Scholar
  4. 4.
    Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson JF (1997) Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 24(3):555–559PubMedGoogle Scholar
  5. 5.
    Vargas-Alarcón G, Fragoso JM, Cruz-Robles D, Vargas A, Lao-Villadóniga JI, García-Fructuoso F, Ramos-Kuri M, Hernández F, Springall R, Bojalil R, Vallejo M, Martínez-Lavín M (2007) Catechol-O-methyltransferase (COMT) gene haplotypes in Mexican and Spaniard patients with fibromyalgia. Arthritis Res Ther 9:R110PubMedCrossRefGoogle Scholar
  6. 6.
    Senna ER, De Barros Al, Silva EO, Costa IF, Pereira LVB, Ciconelli RM, Ferraz MB (2004) Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 31:594–759PubMedGoogle Scholar
  7. 7.
    Russell IJ (1998) Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 315:377–384PubMedCrossRefGoogle Scholar
  8. 8.
    Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N (2003) Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 23:104–107PubMedGoogle Scholar
  9. 9.
    Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of new selective COMT inhibitors. Pharmacol Rev 51:593–628PubMedGoogle Scholar
  10. 10.
    Roussos P, Giakoumaki SG, Bitsios P (2009) Tolcapone effects on gating, working memory, and mood interact with the synonymous Catechol-O-methyltransferase rs4818C/G polymorphism. Biol Psychiatry 66:997–1004PubMedCrossRefGoogle Scholar
  11. 11.
    García-Fructuoso FJ, Lao-Villadóniga JI, Beyer K, Santos C (2006) Relationship between catechol-O-methyltransferase genotypes and fibromyalgia’s severity. Reumatol Clin 2:168–172CrossRefGoogle Scholar
  12. 12.
    Nackley AG, Shabalina SA, Lambert JE, Conrad MS, Gibson DG et al (2009) Low enzymatic activity haplotypes of the human Catechol-O-methyltransferase gene: enrichment for marker SNPs. PLoS ONE 4(4):e5237PubMedCrossRefGoogle Scholar
  13. 13.
    Matsuda JB, Barbosa FR, Morel LJF, França SC, Zingaretti SM, Marins M, Da Silva LM, Pereira AMS, Fachin AL (2010) Serotonin receptor (5-HT2A) and catechol-O-methyltransferase (COMT) gene polymorphisms: triggers of fibromyalgia? Braz J Rheumatol 50(2):141–149Google Scholar
  14. 14.
    Bennett R (2005) The Fibromialgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 23(Suppl.39):S154–S162PubMedGoogle Scholar
  15. 15.
    Nackley AG, Tan KS, Fecho K, Flood P, Maixner W (2005) COMT modulates pain sensitivity and cytokine production through both ß2 and ß3 adrenergic receptors. Washington, DCGoogle Scholar
  16. 16.
    Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W (2007) Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 128:199–208PubMedCrossRefGoogle Scholar
  17. 17.
    Cohen H, Neumann L, Glazer Y, Ebstein RP, Buskila D (2009) The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. Clin Exp Rheumatol 27(5 Suppl 56):S51–S56PubMedGoogle Scholar
  18. 18.
    White KP (1999) Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. Arthritis Rheum 42:76–83PubMedCrossRefGoogle Scholar
  19. 19.
    Martinez JE, Ferraz MB, Saio EI, Atra E (1994) Avaliação seqüencial do impacto de fibromialgia e artrite reumatóide na qualidade de vida. Braz J Reumatol 34:309–316Google Scholar
  20. 20.
    Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu Y, Koeppe RA, Stohler CS, Goldman D (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240–1243PubMedCrossRefGoogle Scholar
  21. 21.
    Shastry BS (2006) Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6:16–21PubMedCrossRefGoogle Scholar
  22. 22.
    Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464–468PubMedCrossRefGoogle Scholar
  23. 23.
    Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3:739–748PubMedCrossRefGoogle Scholar
  24. 24.
    Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221PubMedCrossRefGoogle Scholar
  25. 25.
    Pinsonneault J, Sadee W (2003) Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. AAPS PharmSci 5:E29PubMedCrossRefGoogle Scholar
  26. 26.
    Meyer UA (2004) Pharmacogenetics—five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669–676PubMedCrossRefGoogle Scholar
  27. 27.
    Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645–656PubMedCrossRefGoogle Scholar
  28. 28.
    Lesko LJ, Woodcock J (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 3:763–769PubMedCrossRefGoogle Scholar
  29. 29.
    Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 9:9Google Scholar
  30. 30.
    Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat Rev Genet 4:937–947PubMedCrossRefGoogle Scholar
  31. 31.
    Sadée W, Dai Z (2005) Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14:207–214CrossRefGoogle Scholar
  32. 32.
    Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P (2008) Genetic variation in the Catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 4:64. doi: 10.1186/1744-8069-4-64 PubMedGoogle Scholar
  33. 33.
    Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73–78PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Flávia Regina Barbosa
    • 1
  • Josie Budag Matsuda
    • 1
  • Mendelson Mazucato
    • 2
  • Suzelei de Castro França
    • 1
  • Sônia Marli Zingaretti
    • 1
  • Lucienir Maria da Silva
    • 3
  • Nilce Maria Martinez-Rossi
    • 2
  • Milton Faria Júnior
    • 1
  • Mozart Marins
    • 1
  • Ana Lúcia Fachin
    • 1
    Email author
  1. 1.Unidade de BiotecnologiaUniversidade de Ribeirão PretoRibeirão PretoBrazil
  2. 2.Departamento de Genética-FMRP-USPRibeirão PretoBrazil
  3. 3.Hospital Electro BoniniUniversidade de Ribeirão PretoRibeirão PretoBrazil

Personalised recommendations